The global antibiotics sector is undergoing several challenges and the cefalotin market is equally influenced by these changes. Since the advent of 2024, the key players in antibiotics have raised their price quotations to sustain in the market. The US market, during the initial phase of 2024 followed the trail of the previous years as the players introduced their price hikes. However, the federal government took some measures to curb this price increase, which was yet to showcase any effect on the price trend of cefalotin.
In South Korea, the demand for cephalosporin-based antibiotics like cefalotin exceeded the supply, and thus, the deepening shortage of the commodity led to a substantial effect on its pricing trajectory. Many domestic, local, and overseas pharmaceutical companies halted and downsized their cephalosporin production as the surge in the cost of raw materials since the fourth quarter of 2023 has decreased their profitability. The market players also anticipate that the market may continue to experience this shortage as there are no signs of easing in the prices of feedstock materials.